These include insulin sensitizers-biguanide, metformin and thiazolidinediones, insulin secretagogues-sulfonylureas, and non-sulfonylurea secretagogues, (GLP-1) agonists, DPP4 inhibitors, and pramlintide, an analogue of the peptide amylin that the beta cell co-secretes with insulin, is commonly recommended for use with insulin in both type 1 and type 2 diabetes (Alam et al., 2014). This evidence concerns the gene INS and type 2 diabetes mellitus.